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Iron	  is	  an	  essential	  dietary	  element	  that	  supports	  oxygen	  transport,	  nutrient	  
metabolism	  and	  protein	  synthesis;	  however,	  dysregulation	  of	  iron	  biology	  can	  be	  
detrimental	  to	  health.	  The	  importance	  of	  iron	  homeostasis	  is	  particularly	  apparent	  
in	  the	  brain	  where	  deficiencies	  result	  in	  impaired	  cognition	  and	  accumulations	  are	  
associated	  with	  neurodegenerative	  diseases.	  	  Despite	  the	  observation	  that	  altered	  
iron	  status	  is	  associated	  with	  impaired	  brain	  health,	  little	  is	  known	  about	  what	  
drives	  iron	  dysregulation	  in	  the	  brain.	   
Obesity	  is	  associated	  with	  increased	  risks	  for	  altered	  systemic	  iron	  status	  and	  
neurodegeneration,	  but	  the	  effects	  of	  obesity	  on	  iron	  biology	  in	  the	  brain	  are	  
uncertain.	  The	  following	  study	  characterizes	  changes	  in	  brain	  iron	  biology	  resulting	  
from	  high	  fat	  diet-­‐induced	  obesity	  in	  a	  mouse	  model.	  The	  key	  findings	  from	  this	  
study	  include	  the	  observation	  of	  attenuated	  iron	  concentration	  changes	  between	  
late	  development	  and	  adulthood,	  as	  well	  as	  increased	  alpha-­‐synuclein	  expression,	  
and	  evidence	  of	  lipid	  peroxidation	  in	  certain	  iron-­‐rich	  brain	  regions	  of	  the	  obese	  
mice	  compared	  to	  controls.	  	  These	  findings	  demonstrate	  that	  obesity	  is	  sufficient	  to	  
alter	  brain	  iron	  biology	  and	  that	  the	  alterations	  occur	  in	  a	  regionally	  differentiated	  
manner.	  Further,	  the	  observation	  of	  elevated	  alpha-­‐synuclein	  and	  lipid	  peroxidation	  
in	  regions	  where	  iron	  biology	  is	  also	  altered	  indicates	  that	  the	  changes	  brought	  on	  
by	  obesity	  may	  be	  involved	  in	  iron-­‐related	  neurodegenerative	  processes.
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CHAPTER I 
	  
INTRODUCTION 
 
 
Apart from the known causes of altered iron status (e.g. insufficient dietary iron, 
impaired absorption of dietary iron, blood loss, and genetic abnormalities) a link to 
obesity has also been established [1–5]. The cause of the systemic iron deficiency seen in 
obesity has more recently been associated with low-grade chronic inflammation and 
increased serum concentrations of the iron regulatory protein hepcidin [2–4,6]. However, 
a full understanding of the iron regulatory changes brought on by obesity and, in 
particular, those that affect the brain have yet to be characterized and warrant further 
study.   
Research has demonstrated that certain regions of the normal brain contain higher 
iron concentrations than the brain as a whole [7,8].  The iron-rich regions include the 
substantia nigra, striatum, hippocampus, and thalamus among others.  Erikson et al. and 
Piñero et al. reported that these brain regions are differentially affected by neonatal iron 
deficiency and subsequent iron repletion [9,10]. The effects of iron deficiency during 
infancy on brain development and cognition have been studied and shown to cause 
neurological impairments that can last decades [11]. Excessive iron in the brain can also 
be detrimental. Neurodegenerative diseases have been associated with the accumulation 
of iron in specific brain regions; however, the relevance of these findings to the disease 
etiology is currently unclear [12]. Separately, obesity and high fat intake are associated
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with two of the most prominent neurodegenerative diseases, Alzheimer’s disease and 
Parkinson’s disease [13–16]. Therefore, our study was conducted to observe the effects of 
high fat diet-induced obesity on brain iron biology to determine if there is a link between 
obesity-induced altered brain iron and neurodegenerative processes. The working model 
below characterizes the current knowledge and gaps to be addressed (Figure 1.1.).  
 
Figure: 1.1. 
Working Model. 
Obesity is 
associated with an 
increased risk of 
iron deficiency and 
alterations in 
systemic iron 
biology likely due to 
chronic 
inflammation 
[1,2,6]. A) To study 
the effects of 
obesity on brain iron 
biology we used a 
mouse model 
(C57BL/6), which is 
known to develop 
obesity [17,18] with 
characteristics similar to human physiological changes including: B) elevated 
inflammatory markers [2,6,19,20],  alterations in iron metabolism proteins [20,21], and 
iron deficiency without anemia [1,22,23]. C) Obesity is also known to increase the risk of 
developing neurodegeneration [13,15,16] D) We hypothesized that the changes in 
systemic iron biology brought on by obesity extended to regional brain iron biology in 
adolescence and adult mice. E) Further, using assays to determine if alpha-synuclein gene 
expression and lipid peroxidation were increased, we sought to associate changes in 
regional brain iron biology with indications of neurodegenerative disease. F) Acute 
inflammation has been shown to alter brain iron biology in a manner that is differentiated 
across cell types and brain regions, lending further support to our hypothesis that obesity 
may alter iron biology in the brain in a regionally distinct manner [24–27]. G) Our study 
focused on four iron-rich brain regions [7,8] that are associated with Alzheimer’s disease 
(Hippocampus, HC; Thalamus, TH) [28–32], and Parkinson’s disease (Midbrain, MB; 
Striatum, ST) [7,33–38]. (Brain image courtesy of www.gensat.org) 
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We utilized a well-characterized murine model (C57BL/6J) of high fat diet-
induced obesity to assess changes in brain iron biology [17,18]. The aims of our study 
were to: 
 
1. Determine changes in brain iron concentration and the expression of genes 
related to iron biology in four iron-rich regions of the mouse brain including: 
the midbrain, the thalamus, the striatum, and the hippocampus, in mice 
experiencing altered systemic iron biology associated with obesity [7,8]. 
2. Evaluate iron-related changes in these brain regions across developmental 
stages: adolescent (6 week) and adult (20 week), within and across dietary 
groups and time points.  
3. Compare alpha-synuclein gene expression and a marker of lipid peroxidation 
between the obese and control mice to determine if early signs of 
neurodegenerative disease are present in the brain regions of obese mice.   
 
Based on previous un-published data, we hypothesized that obesity would alter 
regional iron accumulation with a significant increase in the midbrain and varying 
degrees of change in the remaining regions. Additionally, we hypothesized that the 
effects of obesity on brain iron biology would differ across the two developmental time 
points. Finally, by including the assessment of alpha-synuclein, a protein involved in the 
development of Lewy bodies, and a metabolite of lipid peroxidation (i.e. F2-
isoprostanes), we sought to provide insight into whether or not changes in brain iron 
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biology brought on by high fat diet-induced obesity set the stage for future neurological 
impairment. The overall study design is depicted in Figure 1.2, below.  
 
 
Figure 1.2. Study Design. Twenty-one day old male C57BL/6J mice (n=40) were 
randomly divided into two dietary groups, high fat diet (60% of Kcal from fat) and low 
fat control diet (10% Kcal from fat). After 6 weeks (6 wk) of feeding, brain, liver, spleen, 
and plasma samples were collected from ten adolescent mice in each dietary group. The 
tissues were assessed for iron concentration (µg/mg protein) and iron-related gene 
expression. Sample collection and analysis was repeated after 20 weeks (20 wk) of diet in 
the remaining adult mice. Separately, lipid peroxidation metabolites were assessed in the 
20 week midbrain and hippocampus using an F2-isoprostane assay conducted by the lab 
of Dr. Michael Aschner. (Brain image courtesy of www.gensat.org) 
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CHAPTER II 
 
REVIEW OF THE LITERATURE 
 
 
Introduction 
 
 
 Iron is an essential dietary element that, when associated with select proteins, 
helps to safely transport oxygen, metabolize macronutrients, and synthesize proteins 
including neurotransmitters in the human body. Iron’s ability to support these functions 
comes largely from its ability to participate in single electron chemistry by readily 
converting between its ferrous (Fe+2) and ferric (Fe+3) forms. This same attribute allows 
free, unbound iron to catalyze the generation of reactive oxygen species that can be 
detrimental to human health. The body has developed an array of proteins to govern the 
metabolism of iron; however, this system is susceptible to environmental influences that 
may result in poor iron management.  
Obesity is known to increase the risk of systemic iron deficiency in a manner that 
is not fully understood [1,2]. Further, the effect of obesity on brain iron biology has yet to 
be reported. The following literature review will discuss what is known about the normal 
biology of iron in the brain, the effects of altered iron status on regional brain iron 
concentration, associations between obesity and systemic iron status, as well as 
associations between obesity and neurodegeneration. The cumulative evidence indicates 
that obesity has the potential to alter iron status in the brain, likely in a regional manner, 
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and that the susceptible brain regions are implicated in neurodegenerative diseases for 
which obesity is a risk factor.  
 
 Brain Iron Transport 
 
 
The unique anatomy of the brain including the blood brain barrier (BBB), glial 
cells, ventricles, and cerebrospinal fluid produces an environment that is distinct from the 
remainder of the body. Despite these physical distinctions, the brain expresses many of 
the same iron metabolism proteins that are active elsewhere in the body including the 
transport protein transferrin (Tf), the storage protein ferritin, the export protein 
ferroportin, as well as the membrane receptor proteins transferrin receptor -1 (TfR-1), and 
divalent metal transporter-1 (DMT-1) [8,24,39,40]. Currently, the complete mechanism 
of iron transport throughout the brain is not fully understood. The following will provide 
an overview of key concepts relevant to the current study. 
Iron predominantly enters the brain at the BBB, a system of microvasculature 
related to the capillary system found elsewhere in the body. Structurally, the BBB can be 
thought of as a multi-layer system which coordinates to form a unique and highly 
selective barrier transport system [reviewed in [41]]. Research indicates that the 
predominant pathway for iron to enter the brain parenchyma is through the action of TfR-
1 on the luminal side of the capillary endothelial cells that form the BBB [42,43]. The 
path across the endothelial cell involves the formation of an endosome around the holo-
transferrin molecule where iron is released by decreased pH [44].  It is notable that the 
existence of DMT-1 in the BBB endothelial cells is debated [45–47]. Lack of DMT-1 
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would require participation of an undetermined transporter to release iron from the 
lysosome into the cytoplasm. Once free of the endosome, iron is available for transport 
out of the epithelial cell by ferroportin; however, it must be oxidized by either 
ceruloplasmin or hephaestin prior to entering the brain circulation [40,48].  Studies using 
radiolabeled iron show that the holo-transferrin is not shuttled through the endothelial cell 
[49]. Rather, the apo-transferrin TfR-1 complex is predominately transported back into 
the luminal side of the endothelial cells where apo-transferrin is released into the 
plasma[49].  
The brain is fully equipped to distribute iron even without the influx of systemic 
iron transport proteins. Brain-derived transferrin is produced by neurons, 
oligodendrocytes, astrocytes, and the choroid plexus and thought to act as the primary 
intercellular transporter of iron throughout the brain [8,50,51].  Further, neurons, 
astrocytes and microglia express DMT-1 and TfR-1, allowing for the accumulation of 
transferrin bound iron as well as non-transferrin bound iron [27,39,52]. Neurons, 
astrocytes, oligodendrocytes, and microglia all express ferroportin, which functions as the 
primary transporter of iron from the cells into the brain circulation [40,48]. The ventricles 
and choroid plexus have also been shown to be involved in brain iron homeostasis. 
Studies demonstrating the transport of iron into tissues proximal to these structures 
indicate that they may play a role in brain iron accumulation and export via the 
cerebrospinal fluid [8,53].   
In summary, iron biology in the brain shares similarities with systemic iron 
biology including transport proteins, cell surface receptors and the regulatory protein 
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hepcidin. It is therefore possible that environmental stimuli, which have an effect on 
systemic iron biology, may also result in changes to brain iron biology. However, studies 
of iron deficiency and repletion indicate that the regulation of iron in the brain is dynamic 
and involves the consideration of both developmental stage and brain region.  
 
The Brain and Iron Status 
 
 
Research indicates that brain iron biology varies throughout development and that 
brain iron accumulation is associated with the normal aging process [7–10,54]. The 
effects of insufficient iron during the early stages of brain development and cognition 
have been studied and are known to cause impairments that can last decades despite iron 
supplementation [11,55]. Conversely, the pathology of neurodegenerative diseases 
including Alzheimer’s disease and Parkinson’s disease are characterized by 
accumulations of iron in brain regions associated with resultant cognitive or motor 
control impairment. Specifically, Alzheimer’s disease is associated with iron 
accumulations in the hippocampus and Parkinson’s disease with accumulations in the 
substantia nigra, part of the midbrain [28,29,33–35,38].   While these findings underscore 
the importance of maintaining appropriate iron levels in the brain, much remains 
unknown about how the brain responds to altered iron status and the long-term impacts 
on brain health.  
Regional changes in brain iron during deficiency and repletion has been studied in 
Sprague-Dawley rats [9,10].  These studies demonstrated the effects of altered dietary 
iron during early developmental time points (birth to 9 weeks). Interestingly, the regional 
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effects of iron deficiency varied by study with a significant decrease in iron concentration 
and increase in Tf expression in the hippocampus alone in the first study [9]; versus 
significant iron concentration decreases in the substantia nigra, striatum and thalamus in 
the later study [10]. It is notable that the thalamus only responded to deficiency at later 
time points. Response to deficiency and repletion was also heterogeneous within regions 
in the second study with the hippocampus responding to supplementation, but not 
deficiency; while the substantia nigra and striatum generally responded to deficiency but 
not supplementation. Each of these studies used intakes of iron deficient diets that yielded 
severe iron deficiency in a vulnerable developmental stage. The effect of chronic, low-
grade iron deficiency on regional brain biology is unknown and may differ from the 
observations above, particularly at later stages of life when development slows. While 
there still is more to be learned about regional brain iron biology during development, the 
concept of a differentiated response to environmental stress may support a role for the 
iron alterations brought on by obesity in the development of brain region specific 
neurodegeneration.   
 
Obesity and Iron Status 
 
Currently, the Center for Disease Control estimates that over a third of adults and 
17 percent of children in the United States are obese and at increased risk for co-morbid 
disease [56]. Indeed, evidence indicates that obesity increases the risk of adult onset 
diabetes, cardiovascular disease and cancer (reviewed [57]) as well as neurological 
disorders [13,15,16].  In the 1960s, two studies reported markers of decreased iron status 
 10 
in obese adolescent boys and girls [58,59]. This finding was further explored in a 2004 
analysis of the Third National Health and Nutritional Examination Survey (NHANES) 
[1].  The study found that the risk of iron deficiency increased with BMI and that children 
above the 85th percentile had approximately twice the risk of iron deficiency as those 
with normal BMI.  This finding has been supported by several additional studies in 
diverse populations [6,60–63].  The NHANES results, published by Nead et al., are based 
on total iron deficiency, a measure that combined iron deficiency with anemia (IDA) and 
iron deficiency without anemia (ID) [1]. The group also reported the prevalence of IDA 
versus ID in each weight group, which showed that the majority of the affected obese 
individuals were not anemic (i.e. weight above 95th percentile, IDA = 1.1% vs. ID = 
4.4%).   
Obesity-associated iron deficiency has also been demonstrated in adults [4,22,23]. 
Studies of obese individuals undergoing gastric bypass surgery have reported rates of 
preoperative iron deficiency as high as 35% to 43.9% [22,23]. These studies further 
indicate that, within obese populations, younger individuals and women have a higher 
prevalence of iron deficiency than men [22,23]. The higher rate of ID in obese women as 
compared to men is consistent with increased iron needs of women during reproductive 
years. However, the results of a small study (n=50) in postmenopausal obese women 
found elevated serum TfR-1, demonstrating that obesity-induced iron deficiency may 
persist in women beyond the reproductive years [64]. These results indicate that the 
prevalence of iron deficiency in the obese adult population is high and that younger 
individuals and women in general could be more at risk. 
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Attempts have been made to determine how obesity influences iron status.  A 
systematic review of obesity’s effect on iron status involving 25 studies concluded that 
obesity-related iron alterations exist and are suggestive of an inflammation-mediated 
pathway but too few studies included inflammatory markers to draw conclusions [2]. 
Findings in obese children (6 -14 years of age) in Switzerland found that changes in 
hepcidin levels and inflammation assessed by C-reactive protein (CRP) and interleukin-6 
(IL-6) were driving the ID rather than low dietary iron intake [6]. Additionally, a 
convenience sample of 234 obese adults versus normal weight controls showed that the 
obese individuals had lower serum iron and higher serum TfR-1, CRP, and ferritin, 
findings consistent with inflammation-mediated iron deficiency [4].  While the 
mechanism has not been completely elucidated, the current understanding is that the 
chronic inflammation associated with obesity causes iron deficiency by increasing the 
iron regulatory proteins hepcidin and ferritin, which decrease iron absorption and 
recycling.    
Animal models of obesity and altered iron status have focused on the causes of 
systemic iron deficiency including alterations in iron metabolism protein expression and 
poor absorption.  Findings from a study using C57BL/6 mice fed low fat diet (LFD; 10% 
Kcal from fat) in the control group and high fat diet (HFD; 60% Kcal from fat) to induce 
obesity demonstrated decreased liver non-heme iron, increased expression of hepcidin 
mRNA relative to liver iron, and increased serum amyloid A, an inflammatory marker, in 
the high fat diet group [20]. A separate study using the same mouse model and diet 
showed high fat diet-induced obesity caused systemic ID independent of hepcidin [21]. 
 12 
The study found significant up-regulation of duodenal enterocyte DMT-1 and TfR-1 
mRNA in the high fat diet groups without changes in hepcidin. In addition, two weeks of 
iron supplementation was sufficient to increase expression and serum levels of hepcidin 
in the low fat diet but not high fat diet mice. These findings indicate that the C57BL/6J 
mouse model of obesity develops markers of inflammation and iron deficiency.  
Despite the lack of information on obesity and brain iron biology, studies looking 
at the effects of acute inflammation on brain iron biology provide support for a potential 
role. Recent studies have reported that the inflammatory cytokines tumor necrosis factor 
alpha (TNF-α) and IL-6, which are elevated in obesity, are capable of inducing the 
production of hepcidin in astrocytes and microglia as well as increasing DMT-1 in these 
cells and hippocampal neurons [6,19,24]. At the cellular level, the findings included 
significantly increased iron concentrations in the neurons and microglia. A separate cell 
study went on to show increased iron uptake and retention in astrocytes and microglia 
exposed to TNF-α [27]. Studies in rats further demonstrate that acute inflammation, 
unrelated to brain injury, alters brain iron biology. Both intravenous lipopolysaccharide 
and peripheral abscess have been shown to produce alterations in brain iron biology, 
regional variations in hepcidin expression, and increased expression of iron import and 
storage proteins within hours of administration [25,26].  
While obesity is known to increase the risk of systemic iron deficiency, the effect 
of obesity on iron biology in the brain has not been studied [1,6,22]. Studies suggest that 
inflammation may play a role in the development of obesity-associated systemic iron 
deficiency [2,4,20]. Inflammation has also been shown to illicit changes in brain iron 
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biology in animal and cell culture studies [20,24–27].  However, it is unknown if obesity 
per se is sufficient to affect iron biology in the brain via inflammation or other 
physiological changes. Previous observations relating obesity, iron and 
neurodegenerative disease may provide support for further study as well as potential 
targets to assess in determining the relevance to human disease.  
 
Obesity and Neurodegeneration 
 
 
Emerging findings indicate a role for high fat diet and obesity in 
neurodegeneration with an etiology that is currently uncharacterized [13,65,66]. In a 
global analysis of the brain using magnetic resonance imaging, obesity was found to be 
negatively associated with gray matter and midbrain volume in a population of Japanese 
men (n= 690, gray matter P < 0.001 and midbrain P < 0.05) [66]. Separately, evidence 
exists for the association between obesity and the two most prevalent neurodegenerative 
diseases: Alzheimer’s disease and Parkinson’s disease.  
 
Alzheimer’s Disease 
 
Alzheimer’s disease is the most common cause of dementia in individuals over 
the age of 65. Affecting over five million people in the U.S. alone, Alzheimer’s disease 
had an estimated impact of greater than $200 billion dollars in 2013 [67]. While the 
leading risk factors for Alzheimer’s disease are advanced age (>60 years) and genetic 
predisposition, modifiable environmental factors including vascular disease, diabetes, and 
obesity have all been associated with an increased risk of Alzheimer’s disease [13,68]. 
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Further, a meta-analysis by Loef and Walach summarized the findings of 13 studies to 
determine that midlife overweight and obesity significantly increased the relative risk for 
dementia by RR =1.34 [95% CI 1.08, 1.66] and RR =1.91 [95% CI 1.4, 2.62] respectively 
as compared to normal weight after adjusting for confounders [13]. In addition to being 
an independent risk factor for Alzheimer’s disease, obesity is a known risk factor for 
many of the disease states associated with Alzheimer’s disease and dementia including 
most prominently hypertension, and diabetes [57]. Associations between obesity and 
adult-onset diabetes further support the evidence for obesity’s role in dementia. Meta-
analysis and cohort studies have demonstrated that patients with an impaired glucose 
tolerance test, indicative of insulin resistance and diabetes, were at increased risk for 
Alzheimer’s disease [69,70]. Despite these associations, the mechanisms driving the 
pathogenesis of Alzheimer’s disease continue to be elusive.  
Iron biology may offer some insight into the link between obesity and 
Alzheimer’s disease. Beta-amyloid, a protein component of the plaques seen in 
Alzheimer’s disease, has been shown to have ferroxidase activity [71]. Further, an iron 
response element has been documented in the 5’ untranslated region of the gene for the 
amyloid precursor protein, the protein which is cleaved to form beta-amyloid [71,72].  
Importantly, the presence of redox active iron in senile plaques and tangles has been 
demonstrated in Alzheimer’s disease [73]. More recently, a series of studies 
demonstrated that gestational and neonatal systemic iron deficiency activates multiple 
Alzheimer’s related genes in the hippocampus of mice and rats [74,75].  Further research 
is warranted to determine whether the alterations in brain iron biology brought on by 
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obesity are capable of influencing any of these targets, thus setting the stage for 
Alzheimer’s disease.  
 
Parkinson’s Disease 
 
Parkinson’s disease is a chronic, degenerative movement disorder characterized 
by tremor, rigidity, slow movement, and postural instability that is the result of the loss of 
dopamine synthesizing cells in the substantia nigra, a brain region noted for high iron 
concentration [7,8]. Currently, the most prominent risk factor for Parkinson’s disease is 
advanced age as only 5 - 10% of cases can be tied to known genetic mutations [76,77].  It 
is estimated that over one million people in the U.S. suffer from Parkinson’s disease and 
that this number may continue to increase as the population ages [78]. Despite an 
increasing understanding of the pathophysiology of Parkinson’s disease in recent years, 
the underlying etiology of the disease remains elusive, and there is no cure.  
The role of obesity as a risk factor for Parkinson’s disease is currently unclear. 
Prospective epidemiological studies of adiposity in midlife and resultant Parkinson’s 
disease risk have had mixed results. In 2002, Abbot et al. found a significant association 
between midlife triceps skin fold thickness and future risk of Parkinson’s disease in 
Japanese Americans using data from the Honolulu Heart Program [16]. Two years later 
Chen et al. was unable to find an overall association between BMI or central obesity and 
the development of Parkinson’s disease using a data from the Health Professionals 
Follow-up Study and the Nurses’ Health Study [15]. However, there were associations 
between measures of central adiposity and the risk of Parkinson’s disease in the non-
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smoking subset of this data [15].  Palacios et al. (2011) confirmed the lack of overall 
association between obesity, waist circumference, or diabetes and Parkinson’s disease 
using data from the Cancer Prevention Study II Nutrition Cohort, but notes that results 
may have been limited by biases of self-reporting [79].  
 Environmental exposure risks for Parkinson’s disease include increased relative 
risk factors for diets high in animal fat, but the evidence is not conclusive. A recent case-
control study in Japan showed some evidence of decreased risk of Parkinson’s disease in 
a dietary pattern described as “healthy” but no associations with “Western” or “light 
meal” patterns [65].  Previous studies looking at nutrient categories found increased risk 
of Parkinson’s disease related to high fat diets as summarized in Table 2.1. 
 
Table 2.1. High Fat Diet and the Risk of Parkinson’s Disease 
 
Dietary Exposure Risk: Odds Ratio (CI)  Study 
Animal fat 
 
5.3 (1.8, 15.5) n=110 [80] 
High Animal Fat 
(ice cream, soft and hard 
cheese, butter, eggs, 
milk, beef, pork, liver) 
 
3.42 (1.38, 8.51) n=156 
(note P = 0.15)  
 
[81] 
Total Fat 
 
1.94 (1.05, 3.58) N=126  
[14] Cholesterol  
2.11 (1.14, 3.90) N=126 
Iron 1.88 (1.05, 3.38) N=126 
 
 
 
Finally, a study which looked at the relationship between iron and high dietary 
intake of animal fats found a nine fold increased risk of Parkinson’s disease when 
transferrin saturation was low and fat intake was high as compared to those with low fat 
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intake (OR, 9.0; 95% CI, 2.7-29.9) [82]. Further research is needed to clarify these results 
and determine what role high fat diets play, if any, in the development of Parkinson’s 
disease.  
Despite a lack of strong epidemiological data relating diet and obesity to 
Parkinson’s disease, it is clear that alterations in iron biology are relevant to the disease. 
Elevated iron concentration in the substantia nigra is a consistent characteristic of the 
disease pathology [33–35]. Further, gathering evidence demonstrates that alpha-
synuclein, a protein that has been implicated in Parkinson’s disease by genetics and 
pathological findings, is also associated with iron metabolism [83–88].  
 
Alpha-Synuclein 
 
Alpha-synuclein is one of the primary components of Lewy bodies and Lewy 
nurites, which are aberrant intracellular protein accumulations [85]. Alpha-synuclein 
pathology is characteristic of a number of neurodegenerative diseases including: 
Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease [85,89]. Recently, 
alpha-synuclein has been shown to associate with the neuronal presynaptic membrane 
and function in dopamine metabolism [90,91]. Further, alpha-synuclein has been shown 
to be more abundant in excitatory rather than inhibitory neurons in the hippocampus [92].  
Work in animal models and cell culture has linked alpha-synuclein to iron biology 
as well as shown a potential role for the protein in the generation of reactive oxygen 
species. A small study, using the C57BL/6J mouse model of obesity, demonstrated that 
alpha-synuclein is upregulated in obese mice along with other dopamine transport related 
 18 
genes [93].  Recently, alpha-synuclein has been shown to possess ferrireductase activity 
[87]; and a structure resembling an iron response element has been characterized in the 5’ 
un-translated region of the alpha-synuclein gene [88].  Further, the most prevalent form 
of alpha-synuclein found in Lewy bodies involves the posttranslational phosphorylation 
of serine 129 [86]. This modification results in increased binding affinity for divalent 
metals including iron [94].  Pertinent to neurodegeneration, alpha-synuclein, but not other 
synucleins, has been shown to generate hydroxyl radicals when incubated with iron (II) in 
vitro [95]. 
Combined, the observations of increased risk of neurodegeneration and iron-
related attributes in amyloid precursor protein as well as alpha-synuclein provide 
intriguing links between obesity and iron regulation in neurodegenerative disease. While 
a complete understanding of the etiology of neurodegenerative disease remains unclear, 
evidence relating alpha-synuclein and thus Lewy body pathology to obesity and iron 
biology is building. Assessing the impact of obesity on the expression of alpha-synuclein 
may provide useful insights into sporadic neurodegenerative disease.  
 
Conclusion 
 
As described in the preceding sections, associations between obesity, iron, and the 
proteins associated with neurodegenerative disease indicate a potential interplay that 
warrants further study. Obesity is known to alter systemic iron biology in children and 
adults. It is likely that obesity will impact brain iron since similar proteins actively 
regulate iron in the brain as in the remainder of the body and severe iron deficiency 
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results in decreased iron concentration in the brain; however, this is not certain. Further, 
overnutrition induced obesity is also associated with increased risks for Alzheimer’s 
disease and Parkinson’s disease. Each of these diseases is known to present with high 
iron concentrations in the affected brain regions. Finally, key proteins in Alzheimer’s 
disease and Parkinson’s disease have been shown to be influenced by obesity, and 
associate with iron.  
Direct assessment is necessary to better understand the associations between 
obesity and brain iron biology. Such an assessment should take into account the regional 
nature of iron biology in the brain and observe any changes in the common iron 
regulatory proteins. Assessing changes in expression of a neurodegenerative disease 
related protein that is also associated with iron, like alpha-synuclein, as well as assays for 
oxidative stress would provide a insight into the relevance of altered iron status to disease 
states. 
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CHAPTER III 
 
THE EFFECTS OF DIET-INDUCED OBESITY ON REGIONAL BRAIN 
IRON BIOLOGY 
 
 
Abstract 
 
 
The importance of iron homeostasis is particularly apparent in the brain where 
deficiencies result in impaired cognition and accumulations are associated with 
neurodegenerative diseases.  Obesity is associated with increased risks for altered iron 
status systemically as well as neurodegenerative disease, but the effects of obesity on iron 
biology in the brain have yet to be studied.  The following study examined the effect of 
obesity on brain iron biology by focusing on changes in regional brain iron concentration 
and the expression of iron metabolism proteins at two time points in a mouse model of 
obesity.  C57BL/6J mice were fed a high fat diet for 6 or 20 weeks post weaning to 
induce obesity. Samples were collected at each time point, analyzed, and compared to 
control animals fed a low fat diet. The results indicated that obesity was sufficient to 
attenuate age-related changes in iron concentration seen in control animals between 6 and 
20 weeks in the midbrain and thalamus, but not the hippocampus or striatum. Further, 
markers of neurodegeneration (i.e., alpha-synuclein mRNA expression, F2-isoprostanes) 
were increased in the midbrain at 20 weeks in high fat fed mice as compared to controls. 
These results support previous findings that brain iron biology responds to environmental
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stress in a regionally-distinct manner and indicates that alterations in brain iron biology 
due to obesity may be relevant in neurodegenerative disease 
 
Introduction 
 
 
Obesity is a growing international concern, and it is known that obese individuals 
experience alterations in iron status at an increased rate when compared with the normal 
weight population [1–3]. An association between obesity and iron deficiency has been 
demonstrated in children and adults in developed and underdeveloped countries 
[1,3,2,22].  As early as the 1960s, two studies reported decreased iron status in obese 
adolescent boys and girls in the United States [58,59]. Subsequent studies across diverse 
populations of children have supported these findings including an analysis of the Third 
National Health and Nutritional Examination Survey (NHANES), which found that 
obesity doubled the risk of iron deficiency in children [1,6,60–63]. A retrospective 
review of obese adult patients undergoing gastric bypass found that as many as 43.9% of 
patients were iron deficient [22].  
It is known that iron homeostasis is important to brain health, with deficiencies 
resulting in cognitive impairment and regional excesses found in neurodegenerative 
processes [11,28,29,35,36,38]. Studies have sought to characterize some of the 
physiological changes associated with obesity altered iron biology; however, the effects 
of obesity on brain iron biology have yet to be studied [19,21,96,97].  Due to the brain’s 
relative isolation across the blood brain barrier, the effects of obesity on iron biology in 
the brain may differ from that of the rest of the body [47,49,98]. Thus, we sought to 
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characterize the changes in brain iron biology brought on by high fat diet-induced 
obesity. 
Inside the brain, cells synthesize many of the same iron transport and regulatory 
proteins found throughout the body [12]. For example, transferrin is synthesized 
endogenously by oligodendrocytes [50]; whereas neurons and glial cells, including 
astrocytes and microglia, express both transferrin receptor-1 and divalent metal 
transporter-1 [27,39,52]. Once inside the cell, iron is bound to ferritin, used by cytosolic 
proteins, or taken up by the mitochondria for several uses including ATP synthesis. The 
primary cellular iron exporter in the body, ferroportin, is expressed at the blood brain 
barrier, as well as in glial cells and neurons [24,27,40]. Hepcidin, which regulates 
ferroportin by causing its degradation, is produced by glia cells in the brain [24,99,100]. 
Further, these brain derived proteins react to inflammatory stimuli and signaling with 
regional variations resulting in heterogeneous changes in iron biology which are only 
beginning to be understood [24–27].  
Animal studies have shown that changes in iron concentration also vary by brain 
region in response to dietary iron depletion and repletion as well as inflammatory 
triggers, which may be important to our understanding of neurodegenerative diseases 
[9,10,25,101]. Alzheimer’s and Parkinson’s diseases display the pathological finding of 
regional brain iron accumulation; however it is not known if this accumulation is 
causative or secondary to the disease process [28,29,33–35,38]. Recently, the iron 
regulatory proteins hepcidin and ferroportin were found to be reduced in the brains of 
Alzheimer’s patients [102]. Previously, proteins involved in Alzheimer’s disease 
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(amyloid precursor protein) and Parkinson’s disease (alpha-synuclein) were shown to be 
effected by iron status, possess messenger RNA iron response elements, and display 
ferroxidase/reductase activity [71,72,75,87,88,103]. Beyond these protein related 
associations, the reactive nature of iron itself may be relevant to neuronal degradation as 
free or improperly stored iron is capable of generating free radicals with the potential to 
cause lipid peroxidation and cell death [73,95]. 
 The most prevalent forms of neurodegeneration:, Alzheimer’s disease and 
Parkinson’s disease, have also been linked to obesity and high fat diets, though the 
mechanism(s) remain unknown. Specifically, midlife obesity has been shown by meta-
analysis to increase the risk of Alzheimer’s disease (BMI >30: R = 1.98 [95% CI 1.24, 
3.41]) when compared to normal weight populations [13]. Other obesity-related risk 
factors including a poor dietary fat intake profile (e.g., low in omega 3 fats and high in 
animal and saturated fats) and insulin resistance have also been linked to an increased 
risk of developing dementia or Alzheimer’s disease [69,104]. Parkinson’s disease has 
been associated with increased adiposity as assessed by triceps skinfold thickness at 
midlife; but these results were not confirmed in subsequent studies using larger, more 
diverse populations [15,16,79]. However, dietary habits including higher intake of animal 
fats have been associated with increased risk of Parkinson’s disease with increased odds 
ratio’s ranging from 1.94 (CI: 1.05, 3.58) to 5.3 (CI: 1.8, 15.5) [80,82]. Together these 
findings indicate that modifiable environmental factors including diet and adiposity may 
prove to be relevant predictors or preventative targets for curbing the incidence of 
neurodegeneration in our aging population.   
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Here, we sought to characterize the effects of high fat, diet-induced obesity on 
regional brain iron concentration and regulatory protein expression in C57BL/6J mice at 
6 and 20 weeks post weaning. Developmental research indicates that mice transition from 
the developmental stage into adulthood between 3 and 6 months of age [105]. The first 
time point was chosen to capture the cumulative effects of high fat diet-induced obesity 
during a period know to be vulnerable to changes in iron status (adolescent, late 
development); while the latter time point was chosen to assess affects in the mature brain 
where iron status is thought to be less critical (adulthood) [9,10]. The adult time point 
also provides physiologic data that may be used to support or refute previous 
epidemiological studies implicating midlife obesity as a risk factor for neurodegeneration 
[13,15,16]. The comparison of the data across two time points allowed for the 
observation of changes in regional iron concentration as the animals aged.  
This study provides novel evaluation of brain iron biology using a well 
characterized mouse model of obesity to assess alterations in iron biology in four regions 
of the mouse brain that have been associated with Alzheimer’s disease (hippocampus, 
thalamus), Parkinson’s disease (midbrain-including substantia nigra, striatum) [7,8,28–
36,38]. Additionally, alpha-synuclein gene expression and lipid peroxidation were 
assessed to determine if altered iron status was associated with in vivo markers of 
neurodegeneration [95,106].  
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Methods 
 
 
 
 
 
Figure 3.1. Study Design. Twenty-one day old male C57BL/6J mice (n=40) were 
acquired and randomly divided into two dietary groups, high fat diet (60% of Kcal from 
fat) and low fat control diet (10% Kcal from fat). After six weeks of feeding, brain liver, 
and spleen tissues as well as plasma samples were collected from ten mice in each dietary 
group. The tissues were assessed for iron concentration (µg/mg protein) and iron 
metabolism related gene expression. Sample collection and analysis was repeated after 
twenty weeks of diet in the remaining mice. Separately, lipid peroxidation metabolites 
were assessed in the 20 week midbrain and hippocampus using an F2-isoprostane assay 
conducted by the lab of Dr. Michael Aschner. (Brain image courtesy of www.gensat.org) 
 
 
Animals 
 
Prior to initiation of the study, approval for all animal care and procedures was 
obtained from the University of North Carolina at Greensboro’s Animal Care and Use 
Committee. Male weanling (post-natal day 21) C57BL/6J mice (n=40) were purchased 
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from Jackson Laboratory (Bar Harbor, ME). The mice were randomly divided into two 
dietary groups, housed in pairs and provided bedding materials.  Tail marking was used 
to identify 6 and 20 week groups from the beginning of the study. The housing 
environment was temperature controlled (25 ± 1° C) with automatic lights, which cycle 
off between 1800 h and 600 h. The mice were visually examined and weighed weekly 
throughout the study. The overall study design is presented in Figure 3.1 above.  
 
Diet 
 
Mice, housed by dietary group, were provided free access to diet and water 24 
hours/day for 6 or 20 weeks.  The control group was fed a low-fat diet (LFD; 10% kcal 
from fat, D12450B; Research Diets) and the experimental group received a high-fat diet 
(HFD; 60% kcal from fat, D12492; Research Diets) according to an established obesity 
model diet [17,18]. The source of the fat in the diets was lard. The diets included the 
same mineral mix (S10026; Research Diets), which provided 37mg of ferric citrate per 
4057 Kcal. The similarity in iron content of the diets was confirmed by graphite furnace 
atomic absorption spectrometry (GFAAS) (Varian AA240, Varian, Inc., USA).  
 
Hematocrit and Plasma 
 
Blood from each mouse was collected in heparinized tubes at the time of sacrifice 
and stored on ice until processed.  Hematocrit was determined by centrifugation of 
heparinized micro-hematocrit capillary tubes (Fisher Scientific; Waltham, MA).  
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Remaining whole blood samples were centrifuged for 15 minutes at 1000 x g to separate 
plasma for iron analysis. The plasma was stored at -80°C.  
 
Tissue Collection 
 
Adipose (epididymal, inguinal, mesenteric, and retroperitoneal depots), liver, and 
spleen were collected, weighed, and flash frozen at the time of sacrifice with help from 
members of the Dr. Michael McIntosh group.  
The brain tissue from each mouse was dissected on an ice-cold tray at the time of 
sacrifice to isolate four iron-rich regions which are known to respond to alterations in 
iron status: midbrain, striatum, thalamus, and hippocampus [9]. Sample tissue was placed 
in pre-labeled, RNAse free collection tubes. The liver, spleen and adipose were also 
collected, weighed, and placed in pre-labeled RNAse free collection tubes. All tissues 
were flash frozen in liquid nitrogen and kept on dry ice for transport to a -80° C freezer 
where they were stored until processing. 
 
Iron Analysis 
 
Adipose, liver, spleen, and regional brain tissue as well as plasma samples were 
processed for iron analysis. The tissue samples were sonicated in cold radio-
immunoprecipitation assay (RIPA) buffer with protease inhibitors to disrupt the tissue. 
Aliquots of the homogenate from each tissue sample were used to determine protein 
concentration using the Pierce Bicinchoninic Acid (BCA) Protein Assay (Thermo Fisher 
Scientific Inc., Rockford, IL) and separately digested in ultra-pure nitric acid (1:10 ratio) 
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for 48 hours in a sand bath (60° C).  Aliquots (20 µl) of digested homogenate were 
further diluted in 2% nitric acid for analysis. Iron concentrations were measured using 
graphite furnace atomic absorption spectrometry (Varian AA240, Varian, Inc., USA). 
Bovine liver (NBS Standard Reference Material, USDC, Washington, DC) 184 µg Fe/g 
was digested in ultrapure nitric acid and used as an internal standard for analysis.  All 
samples and controls were run in triplicate and outlier readings were excluded. Iron 
concentrations are expressed as µg Fe / mg protein.    
 
RNA Isolation and cDNA Synthesis 
 
RNA was isolated from the flash frozen regional brain tissue (right hemisphere) 
as well as weighed samples of liver tissue. The RNeasy® Lipid Tissue Mini Kit (Qiagen 
Inc., Valencia, Ca), QIAzol® Lysis Reagent (Qiagen Inc., Valencia, Ca), and stock 
chloroform were used to extract the RNA from all tissue samples according to the 
manufacturers protocol with the following alterations: tissues were sonicated in QIAzol 
Lysis Reagent; flow-through centrifugation was conducted for 30 rather than 15 seconds, 
where indicated; the optional membrane drying step was utilized; and 30 µl of RNase-
free water was used to elute the RNA from the filter. Immediately following extraction 
RNA concentration and purity was determined by spectrophotometric analysis. An 
aliquot containing 2 µg of RNA was extracted from each sample and reverse transcribed 
using the Applied Biosystems High Capacity cDNA Reverse Transcription Kit (Life 
Technologies, Carlsbad, Ca) per the manufacturers protocol. Sample cDNA was used 
immediately or stored at -80° C.  
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Real-Time Polymerase Chain Reaction (RT-PCR) 
 
RT-PCR gene expression assays were conducted with 20 ng of cDNA using 
TaqMan® Universal Master Mix II (Life Technologies, Carlsbad, Ca) and gene assays 
according to the manufacturer’s protocol. The following iron metabolism related 
TaqMan® gene expression assays (Life Technologies, Carlsbad, Ca) assays were 
evaluated: hepcidin (Mm00519025_m1); transferrin receptor-1 (Mm00441941_m1); 
divalent metal transporter-1 (Mm00435363_m1); ferritin H (Mm00850707_g1); ferritin L 
(Mm03030144_g1); ferroportin (Mm00489837_m1); alpha-synuclein 
(Rn00560930_m1). All assays were confirmed as appropriate for use in murine species. 
Control and target assays were validated on excess sample tissue. 18s gene assay 
(Hs99999901_s1) was selected as the appropriate endogenous control. Relative gene 
expression was quantified using the delta-delta Ct method.   
 
F2-Isoprostane Assay 
 
 Isoprostane analysis was conducted in the lab of Dr. Michael Aschner at the 
Albert Einstein College of Medicine New York, NY using a gas chromatography/mass 
spectrometry with selective ion monitoring method previously described by Morrow and 
Roberts, 1999 and more recently outlined by da Silva Santos et al. 2014 [106,107].    
 
Data Analysis 
 
Body weight, iron concentration, and gene expression were analyzed using the 
statistical software package SPSS, Version 22 (Chicago, IL). Student’s t-test was used to 
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evaluate mean differences in body weight and mRNA expression between LFD and HFD 
groups. A repeated measures ANOVA was used for the initial analysis of brain iron 
concentrations with distinct brain regions serving as the within group variable and diet as 
the between variable. This analysis was followed by a one-way analysis of variance 
(ANOVA), which was used to analyze the iron concentration data across time points and 
between diets within each brain region individually. The systemic iron concentrations 
were also analyzed using one-way ANOVA. The significance threshold was set at P < 
0.05 for all analysis.    
 
Results 
 
 
Descriptive Data 
 
 
Mice fed the HFD weighed significantly more than mice fed the LFD ( P < 
0.001) (Table 3.1). At 6 weeks HFD mice weighed 25% more on average than the LFD 
controls (HFD, 30.6 ± 0.4 g; LFD 26.2 ± 0.3 g; P < 0.001) and 32% more than LFD 
controls by 20 weeks (HFD, 52.2 ± 0.8 g; LFD, 39.6 ± 1.1 g; P < 0.001). An analysis of 
fat depots (combined: epididymal, inguinal, mesenteric, and retroperitoneal) showed a 
significant accumulation of white adipose tissue (WAT) in the HFD group as compared 
to LFD at both 6 and 20 weeks ( P < 0.001) (Table 3.1).  Liver weight was also 
significantly increased in the HFD group at 20 weeks compared to the LFD group (LFD 
1.71 ± 0.14 g, HFD 2.80 ± 0.20 g; P < 0.05).   
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Table 3.1. Total Weight and Adipose Weight by Diet 
 
Age Total Body Weight (g)  Adipose Tissue (g) 
 LFD HFD LFD HFD 
6 wk 26.2 ± 0.30 30.7 ± 0.39‡ 1.1 ± 0.11 3.0 ± 0.20‡ 
20 wk 39.6 ± 1.12 52.2 ± 0.79‡ 4.2 ± 0.32 7.1 ± 0.27‡ 
Body weight (6 wk, n=20; 20 wk, n=10) and combined adipose depot: epididymal, 
inguinal, mesenteric, and retroperitoneal weight (6 wk, n=10; 20 wk, n=10) in LFD 
versus HFD mice at 6 wk and 20 wk. Values are expressed as mean ± SEM. The  “‡” 
indicates P < 0.001 versus LFD.  
 
 
Systemic Iron Concentration 
 
Iron concentrations for plasma and hematocrit were not significantly different 
between the groups (Table 3.2). Significant deficits in liver and spleen iron levels were 
present in the HFD group as compared to the LFD group at 6 and 20 weeks (liver: 6 wk 
and 20 wk, P < 0.05; spleen: 6 wk and 20 wk, P < 0.001) (Table 3.3.). Liver iron 
concentration was lower in the HFD group compared to the LFD group by 16% and 19% 
at 6 and 20 weeks respectively. Splenic iron concentration was lower by 45% at 6 weeks 
and 54% at 20 weeks as compared to LFD.  
 
Table 3.2. Whole Blood Hematocrit and Plasma Iron Concentration 
 
Age Plasma (µg/ml) Hematocrit 
 LFD HFD LFD HFD 
6 wk 5.4 ± 2.38 7.0 ± 1.41 0.47 ± 0.01 0.44 ± 0.02 
20 wk 5.1 ± 0.58 6.3 ± 0.59 0.48 ± 0.01 0.45 ± 0.01 
Whole blood hematocrit (n=6) and plasma iron concentration (6 wk n=5; 20 wk n=6) in 
LFD versus HFD mice at 6 wk and 20 wk. Neither hematocrit or plasma iron 
concentration differed significantly between LFD and HFD groups at either time point. 
Values are expressed as mean ± SEM.  
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Table 3.3. Selected Systemic Tissue Iron Concentration (µg/mg protein) 
 
Age Liver  Spleen Adipose 
 LFD HFD LFD HFD LFD HFD 
6 wk 0.51 ± 0.04 0.43 ± 0.01* 2.09 ± 0.02 1.48 ± 0.08‡ 0.56 ± 0.24 1.01 ± 0.24 
20 wk 0.65 ± 0.03 0.53 ± 0.03* 4.38 ± 0.24 2.39 ± 0.16‡ 0.64 ± 0.08 0.72 ± 0.16 
Iron concentrations assessed by GFAAS in selected tissues from LFD versus HFD mice 
at 6 wk and 20 wk. Liver (6 wk LFD n=5, HFD n=6; 20 wk n=8)  and spleen (6 wk LFD 
n=5, HFD n=6; 20 wk LFD n=9, HFD n=10) tissue iron concentrations were significantly 
lower in the HFD group at 6 wk and 20 wk. Adipose (6 wk n=5; 20 wk LFD n=5, HFD 
n=6) iron concentrations did not differ significantly.  Values are expressed as mean ± 
SEM. The asterisk “*” indicates statistical significance at P < 0.05,  and the  “‡” < P < 
0.001 versus LFD 
 
 
Regional Brain Iron 
 
 
A significant within-subjects main effect of brain region ( P < 0.05) was observed 
using repeated measures ANOVA, indicating that the mean concentrations differed by 
region. Because there was a significant effect of region, further assessment of brain iron 
concentration was conducted for each brain region individually across time-points and 
between diets using one-way ANOVA.  Analysis of the data for the individual regions 
indicated a significant effect of time in the midbrain and thalamus as well as significant 
overall difference between HFD and LFD in the midbrain ( P < 0.05) (Figure 3.2.). A 
significant interaction of diet and time was observed the thalamus (P < 0.05). These 
findings indicate that fluctuations in iron concentrations from 6 to 20 weeks were 
attenuated in the HFD group as compared to the LFD group in the midbrain and thalamic 
regions.  Hippocampus and striatum iron concentrations were unchanged by diet or time. 
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A. 
 
B. 
 
Figure 3.2. Select Regional Iron Concentrations. Iron concentrations in two brain 
regions where significant changes occurred with HFD treatment. A. Midbrain (6 wk, 
LFD n=9; HFD n=9; 20 wk, LFD n=8, HFD n=10) iron concentration was decreased in 
the LFD (control) between 6 and 20 weeks. This change in concentration was attenuated 
in the HFD group. B. Thalamus (6 wk, LFD n=9; HFD n=8; 20 wk, LFD n=9, HFD 
n=10) increased in the LFD (control) group from 6 to 20 weeks, a change that was again 
attenuated in the HFD group. Data were analyzed using one-way ANOVA and Student’s 
t test. Means ± SEM without a common letter differ, P < 0.05.  
 
 
mRNA Expression of Iron Homeostasis Proteins 
 
A comparison of iron transport and storage protein mRNA expression in HFD 
versus age matched LFD mice demonstrated few changes. Overall, there was some 
dysregulation at the 6 week time point in the HFD group. No significant changes in 
mRNA expression were observed in the striatum or the hippocampus at 6 or 20 weeks. 
Midbrain alpha-synuclein mRNA expression was elevated at both 6 and 20 weeks in the 
HFD group (Figure 3.3. A. & B.).  The thalamus mRNA expression showed a significant 
elevation of alpha-synuclein in the HFD versus LFD groups at 6 weeks ( P < 0.05) 
(Figure 3.3. C.), which was not present at 20 weeks (Figure 3.3. D.).  
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A.  Midbrain 6 Weeks 
 
 
 
B.  Midbrain 20 Weeks 
 
 
 
C.  Thalamus 6 Weeks 
 
 
D.  Thalamus 20 Weeks 
 
 
 
Figure 3.3. Brain Iron Metabolism Related mRNA Expression. LFD (gray) and HFD 
(black) Relative mRNA expression was quantified by RT- PCR using the delta-delta Ct 
method for ferritin H (FerH), ferritin L (FerL), ferroportin, transferrin receptor-1 (TfR), 
divalent metal transporter-1 (DMT-1), alpha-synuclein (SNCA). Regions assayed 
included A. midbrain 6 wk (LFD, n=3; HFD n=2; SNCA n=2) B. midbrain 20 wk (LFD, 
n=2; HFD, n=2; SNCA, n=4), C. thalamus 6 wk (n=3), D. thalamus 20 wk (n=3). Alpha-
synuclein was elevated at 6 wk and significantly elevated at 20 wk in the midbrain as 
well as significantly elevated at 6 wk in the thalamus.  Values are expressed as percent 
control ± SEM. The asterisk “*” indicates statistical significance at P <0.05 via 
independent samples t-test between LFD (control) and HFD groups. 
 
Liver mRNA showed a decrease in transferrin receptor -1 and an increase in hepcidin 
expression of the HFD mice at 6 weeks. By 20 weeks transferrin receptor was similar 
between groups and hepcidin was decreased in the HFD compared to controls (Figure 
3.4). 
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A.  Liver 6 Weeks 
 
 
B. Liver 20 Weeks 
 
 
 
Figure 3.4. Liver Iron Metabolism Related mRNA Expression. LFD (gray) and HFD 
(black) Relative mRNA expression was quantified by RT- PCR using the delta-delta Ct 
method for ferritin H (FerH), ferritin L (FerL), ferroportin, transferrin receptor-1 (TrfR), 
divalent metal transporter-1 (DMT-1), alpha-synuclein (SNCA), and hepcidin (Hamp). 
Assays of the liver at A. 6 weeks (n=2) and B. 20 weeks (n=2) showed early, 6 week, 
elevation of hepcidin and decreased TrfR in the HFD group. By 20 weeks the expression 
TrfR was similar to LFD while Hamp was decreased in the HFD group. Values are 
expressed as percent control ± SEM, with control based on expression in the LFD group. 
 
 
F2-Isoprostane Formation 
 
 
Lipid peroxidation, as measured by F2-isoprostane formation, was significantly 
elevated in the midbrains of the HFD exposed animals at 20 weeks as compared to LFD  
( P <0.05) (Figure 3.5.). F2-isoprostanes are stable metabolites of lipid peroxidation and 
thus serve as an indirect measurement of accumulated cellular membrane damage.  
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Figure 3.5. F2-Isoprostane Assessment. F2-Isoprostane concentration (ng/mg protein) 
provides an indirect measurement of lipid peroxidation products in the midbrain (MB) 
and hippocampus (HC) showed significant elevation in the midbrain at 20 weeks (n = 5). 
Values represent means ± SEM; the asterisk “*” indicates statistical significance at P < 
0.05 via independent samples t-test between LFD (gray) and HFD (black) groups. 
 
 
Discussion 
 
 
While the effects of obesity on systemic iron have been studied in animal and 
human models, our observations relating obesity to changes in brain iron biology are 
novel. Further, the systemic iron data that we gathered adds to, and corroborates the 
results of previous studies in the C57BL/6J mice showing that obesity alone is sufficient 
to affect iron status [20,21]. We found that the C57BL/6J model develops obesity-
induced iron deficiency but not anemia, which is in agreement with the most common 
physiological presentation in the epidemiological data [1,22,23].  Further, the observation 
of altered regional iron concentration in conjunction with changes in alpha-synuclein 
expression and increased lipid peroxidation may implicate HFD induced obesity in 
neurodegenerative disease (Figure 3.6).   
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Figure 3.6. Results Summary. Key observations of this study include the following: 1) 
Mice fed a HFD had significant increased body weight and fat depot weight (P < 0.001) 
as well as altered iron status including decreased tissue iron concentrations in the liver ( P 
< 0.05), and spleen ( P < 0.001), with increased hepcidin expression in the liver at 6 
weeks). 2) Iron biology was altered in the HFD midbrain and thalamus (attenuation of 
concentration change seen in the LFD, P < 0.05); 3) alpha-synuclein was elevated in the 
thalamus (6 wk, P < 0.05) and midbrain; 4) lipid peroxidation as assessed by F2-
isoprostane assay was elevated in the midbrain (P < 0.05) of the HFD group compared to 
LFD. These observations indicate that obesity is sufficient to cause alterations in 
systemic iron biology with regionally differentiated results in the brain. Further, the brain 
regions where iron biology was altered also showed signs of neurodegenerative 
processes. (Brain image courtesy of www.gensat.org) 
 
The proposed mechanisms for obesity-related alterations in iron biology include 
increased iron demand during growth, decreased dietary iron absorption, and 
inflammation-associated changes in iron regulation [3,6,21,24,26,108].  While each of 
these factors may play a role, much of the existing human research indicates that low-
grade chronic inflammation alters iron biology [2]. Specifically, work by Yanoff et al. 
demonstrated that obese adults had lower serum iron, higher serum transferrin receptor, 
High Fat 
Diet 
Obesity 
Hippocampus 
& Striatum:  
No Change 
Thalamus: 
  Iron Conc. ! 
between 6 & 20 wk 
 
! Alpha-synuclein 
 (6wk) 
Systemic Iron:  
"  Liver, Spleen  
    (6 & 20 wk) 
! Hepcidin (6 wk) 
Midbrain: 
  Iron Conc. " 
between 6 & 20 wk 
 
!  Alpha-synuclein  
(6 & 20 wk) 
 
!  Lipid Peroxidation 
 (20 wk) 
 38 
and elevated C-reactive protein, which are associated with acute phase changes in iron 
biology [4]. Studies of dietary iron intake show that obesity alters iron status even when 
iron intake is sufficient, which argues against the dietary deficiency hypothesis and casts 
doubt on the notion that growth rate is the cause of the iron deficient status in obese 
individuals [3,6,21].   
Mechanistically, the chronic inflammation associated with obesity is known to 
generate cytokines that increase serum hepcidin concentrations and trigger cellular iron 
sequestration.  In particular, the cytokines TNF-alpha and interleukin-6 have been shown 
to increase hepcidin gene expression systemically and in the brain [24,26,109]. Previous 
studies in the C57BL/6J mouse model have reported increases in the same inflammatory 
markers in obese mice as compared to controls [19]. Our observations revealed increased 
liver hepcidin gene expression in the HFD group at 6 weeks as expected, but a decrease 
at 20 weeks relative to LFD. Previous studies in obese C57BL/6J mice have also found 
conflicting results for liver hepcidin gene expression ranging from no effect (8 weeks 
HFD) to decrease (16 weeks HFD) [20,21]. Chung et al. described a decreased expression 
of hepcidin at 16 weeks of HFD but went on to demonstrate that, relative to non-heme 
iron concentration in the liver, the hepcidin expression was actually higher in the HFD 
mice [20]. While unexpected, our 20 week finding was similar to the 16 week findings of 
Chung et al. where both hepcidin gene expression and liver iron concentration were 
decreased by HFD. These results indicate that liver tissue iron concentration may be 
important in regulating hepcidin levels during obesity.   
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Hepcidin is known to decrease cellular iron efflux by triggering the degradation of 
ferroportin, the only known cellular iron export protein [100].  Inhibiting ferroportin on 
the surface of intestinal enterocytes decreases the bioavailability of dietary iron, placing 
additional demands on endogenous iron to maintain homeostasis. In our study, low iron 
concentrations were found in the liver and spleen of HFD mice compared to LFD mice, 
corroborating previous findings [20]. Decreased iron concentrations in these tissues are 
indicative of systemic iron deficiency. However, the lack of a significant change in 
plasma iron concentration or hematocrit values indicates that anemia was not present 
despite tissue iron deficiency.  
With the confirmation that the liver and spleen experienced alterations in iron 
concentration due to HFD induced obesity, we sought to determine if the iron-rich 
regions of the brain experienced similar changes. Iron is known to be distributed in a 
heterogeneous fashion across brain regions and is differentially affected by deficiency as 
well as repletion [7–10]. Further, induced inflammation in the rat results in a hepcidin 
response that differs by brain region with increases in the substantia nigra (midbrain) and 
cortex but not in the hippocampus or striatum [25]. However, these previous studies were 
each designed to evaluate acute or severe environmental stress: dietary iron deficiency or 
induced inflammation. Obesity is a chronic condition, which may produce different 
physiological changes in brain iron biology.  
Using the C57BL/6J mouse model of obesity, we were able to demonstrate that 
HFD induced obesity altered iron concentrations in select regions of the brain when 
compared to LFD control. Our results support previous findings that brain iron biology is 
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region specific [9,10]. Repeated measures ANOVA confirmed that a significant 
difference in iron concentration was present in the four regions of the brain (P < 0.001) as 
well as an interaction effect of region and time (P < 0.05). Further analysis showed that 
HFD induced obesity primarily affected iron concentrations in the midbrain and thalamus 
with little impact on the hippocampus or striatum. These findings were comparable to 
previous work in weanling rats that showed varying the timing of an iron deficient diet 
from nursing, to early and late weaning affected which brain regions became deficient 
[10]. Specifically, the previous study results indicated that the hippocampus and striatum 
were vulnerable during the early pre-weaning period but not the post weaning period and 
the opposite was true for the thalamus. The same study also found that substantia nigra 
(part of the midbrain) was responsive to iron deficiency through the pre and post-weaning 
stages of development.  Alternately, a similar study of iron deficiency in rats found that 
the hippocampus was the most affected region in the post-weaning period [9]. Our study 
differed from previous works because the variable of interest was diet-induced obesity 
and that each diet contained normal levels of iron (37 mg/kg) [110]. Despite the iron 
sufficiency of the diet, a significant change in iron concentration was found in the 
thalamus and the midbrain at the 20 week time point in the HFD mice compared to the 
LFD control mice. Interestingly, changes in the expression of alpha-synuclein mRNA 
fluctuated with the changes in iron concentration in the midbrain and thalamus while 
remaining unchanged in the striatum and hippocampus. This relationship will be 
discussed further in the following sections. 
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Obesity and Midbrain Iron 
 
Taking a closer look at the effect of a HFD on the midbrain, our observations 
include four key alterations: an overall effect of diet on iron concentration; an attenuation 
of regional iron concentration changes resulting in an increase at 20 weeks; elevation of 
alpha-synuclein gene expression; and elevated F2-isoprostanes. The elevated iron 
concentration in the midbrain of the HFD mice compared to the LFD mice is, to the best 
of our knowledge a unique finding. As discussed above, dietary induced iron deficiency 
anemia results in iron deficiencies in the midbrain [10]. However, in the unique setting of 
HFD induced obesity we observed an attenuation of the developmental decrease in 
midbrain iron seen in the LFD group.  This attenuation resulted in a relative increase in 
midbrain iron as compared to the LFD group. This is in contrast to the expected result 
based on prior studies of dietary iron deficiency [9,10].  
The results of our comparative RT-PCR and F2-isoprostanes assays provided 
evidence that alpha-synuclein gene expression and lipid peroxidation were elevated in the 
HDF midbrains. Taken together, these observations are consistent with the pathological 
findings in Parkinson’s disease where iron is known to accumulate in the midbrain 
(specifically the substantia nigra), alpha-synuclein aggregates to form Lewy bodies, and 
oxidative stress is implicated [33–35,85,95,111–113]. Based on these observations 
further assessment of the role of obesity in the etiology of Parkinson’s disease is 
warranted. 
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Obesity and Thalamus Iron 
 
 
Altered iron concentration and increased alpha-synuclein expression in the 
thalamus of HFD mice were also observed in our study. Iron concentration in the 
thalamus of the LFD mice increased between 6 and 20 weeks while in the HFD group it 
remained constant. The elevation of iron concentrations in the LFD control thalamus and 
the decrease in the LFD control midbrain further supports the dynamic regional 
regulation of iron in the brain during normal development. Gene expression of alpha-
synuclein in the thalamus of HFD mice displayed a significant increase at 6 weeks wich 
was not present at 20 weeks compared to the LFD group.  Due to the relationship of 
alpha-synuclein to dopamine transport, our findings may have implications on thalamic 
dopamine biology as discussed below.  
 
Alpha-Synuclein and Brain Iron 
 
 
We evaluated the expression of alpha-synuclein, a protein associated with normal 
and cytotoxic dopamine biology as well as the formation of the Lewy bodies seen in 
Parkinson’s disease due to the regional iron concentration changes in the midbrain and 
thalamus. Studies have demonstrated that alpha-synuclein has characteristics related to 
iron metabolism including ferrireductase activity and an iron response element 
[87,88,103]. Our observation that alpha-synuclein expression was affected in the brain 
regions that experienced changes in iron concentration is also indicative of a relationship 
between alpha-synuclein and brain iron.  Alpha-synuclein is known to decrease with iron 
depletion, which may explain the drop in alpha-synuclein expression in the 20 week HFD 
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thalamus [103]. If the inverse is true, then increased expression of alpha-synuclein may 
confirm the relatively higher iron concentration in the midbrain of the HFD mice as 
compared to the LFD. Further, increased alpha-synuclein expression may also help to 
explain our finding that markers of lipid peroxidation were increased in the midbrain.  As 
a ferrireductase, alpha-synuclein catalyzes the transition of iron to the active ferrous form 
increasing the risk of generating reactive oxygen species [87].   
Alpha-synuclein is also known to affect neuronal dopamine transport in a manner 
related to obesity as well as neurodegeneration [93,113–115].  Increased expression of 
alpha-synuclein and dopamine biology related gene expression was previously reported 
in a model of obesity similar to our study [93]. Further, alpha-synuclein has been 
implicated the coordination of selective dopaminergic neurotoxicity [113]. Iron 
availability is also known to be important to dopamine biology, thus alterations in iron 
biology due to obesity may provide a means to study dopamine related neurotoxicity 
[37,116].  
 
Implications and Future Study 
 
 
 In this initial assessment, we observed that chronic HFD-induced obesity had a 
regional effect on brain iron concentration as well as on markers of neurodegeneration in 
C57Bl/6J mice despite adequate iron availability in the diet. Our results show that HFD 
induced obesity has the ability to alter brain iron biology in a way that may be relevant to 
our understanding of neurological disease, particularly Parkinson’s Disease. The key 
findings of attenuation of iron concentration changes (particularly in the midbrain but 
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also thalamus), increased alpha-synuclein expression, and increased lipid peroxidation in 
the midbrain fit well with the pathology of Parkinson’s disease. The fact that these 
findings occurred at relatively early ages, adolescence (elevated alpha-synuclein) and 
adulthood (alterations in iron biology, elevated alpha-synuclein, and lipid peroxidation), 
suggest that mild chronic neurodegeneration may occur, possibly before clinical 
symptoms manifest. It is also notable that the obesity-related changes iron concentration 
occurred without iron deficiency anemia indicating that changes in the brain may be 
occurring in the absence of overt systemic manifestations. In this scenario the foundation 
of neurodegenerative disease may be developing for years prior to development of 
clinical symptoms.  
Having determined that HFD induced obesity is sufficient to alter brain iron 
biology and markers of neurodegeneration, a broader approach is now necessary in order 
to determine the mechanisms involved and better assess the implications. Specifically, 
measurement of elevated regional glutathione activity, a key endogenous antioxidant, 
would further implicate iron-related reactive oxygen species generation as a cause of lipid 
peroxidation and subsequent neuronal loss in iron-rich areas. Histology of affected 
regions would provide evidence of physiological changes as well as identify the effects 
on specific cell types. Further assessment of proteins known to have links to iron 
metabolism and disease pathology including alpha-synuclein, amyloid precursor protein, 
and beta-amyloid protein would be valuable in understanding the etiology of 
neurodegeneration. Finally, iron deficiency and alterations in alpha-synuclein have been 
shown to impair dopamine transport.  Thus, expanding the scope of these findings to 
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include effects on dopamine biology may provide a link between iron metabolic 
dysregulation and active disease stat
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CHAPTER IV 
EPILOGUE 
 
 
The Erikson lab is focused on understanding how the altered biology of divalent 
elements including iron, copper, and manganese affect brain health. Previous un-
published data from our lab indicated that obese C57BL/6J mice had significantly higher 
concentrations of iron in the midbrain than control mice. The midbrain is known to be an 
iron-rich region that further accumulates iron in the pathology of Parkinson’s disease 
[7,8,33–35]. Our lab sought to confirm and clarify the unpublished results in order to 
determine if obesity was sufficient to alter brain iron biology in a manner that might 
potentiate disease.  During the study design, the scope was expanded from the 
preliminary findings to include four iron-rich brain regions know to be associated with 
neurodegenerative disease states: hippocampus, midbrain, striatum, and the thalamus in 
hopes of elucidating changes in other potentially affected areas [7,8,28–36,38]. The 
primary goals of the study were to: 1) assess the effects of HFD induced obesity on 
regional brain iron biology; 2) evaluate changes in regional brain iron at 6 weeks 
(adolescence) and 20 weeks (adult) time points, and 3) assess markers of 
neurodegeneration for potential links to disease states.  
The theoretical model of our study was built on the knowledge that obese 
individuals experience systemic iron alterations and neurodegenerative disease at an 
increased rate [1–3,22]. Epidemiological data indicates that the alteration in iron 
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biology is likely due to the effect of obesity-induced inflammation on the iron regulatory 
protein hepcidin [2,6]. Further, both iron deficiency and induced inflammation are known 
to effect iron biology in the brain in a regional manner; however, the effects of obesity 
per se on brain iron biology have not yet been reported [9,10,24,25]. Regional brain iron 
concentration is also known to be heterogeneously sensitive to altered iron status during 
development, particularly in regions that accumulate iron in cases of neurodegenerative 
disease [9,10,12,33–35]. Separately, studies have related obesity and high fat diets to 
increased risk of Alzheimer’s disease and Parkinson’s disease respectively, thus 
indicating that adiposity and diet have the potential to influence neurodegeneration, 
though the mechanism is unknown [13,80–82]. We sought to address gaps in the 
literature by determining what effect chronic HFD induced obesity has on regional brain 
iron and if changes in the brain might set the stage for neurodegenerative disease. 
We hypothesized that alterations in brain iron biology brought on by HFD 
induced obesity may be relevant in neurodegeneration. To assess the effects of HFD 
induced obesity on brain iron biology we used a well-characterized animal model of 
obesity (C57BL/6J mouse) fed either a control LFD diet (10% Kcals from fat) or an 
experimental HFD (60% Kcals from fat) iron sufficient diet [17,18]. Care of the mice was 
shared between Steve Fordahl and Wan Shen (to whom we owe many thanks). The HFD 
intervention was started at weaning and the first samples were taken 6 weeks later, near 
the end of adolescence to assess changes during the developmental period. At this point 
the mice were already significantly heavier and showing signs of systemic iron deficiency 
(decreased iron concentration in the liver and spleen, increased hepcidin expression in the 
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liver). While we did not find significant changes in brain iron concentration in these 
samples, we did note increased expression of alpha-synuclein in the midbrain and 
thalamus relative to the LFD controls. Alpha-synuclein, a protein with known 
associations to iron and dopamine biology, is a key constituent in Lewy bodies which are 
characteristic intracellular occlusions in Parkinson’s pathology [72,86,87,90].   
The second set of samples was timed to assess brain iron concentration in adult 
mice after prolonged exposure to the intervention. Interestingly, in these samples we 
found an attenuation of iron concentration changes in the midbrain and thalamus of the 
HFD group as compared to the LFD controls. Specifically, in the LFD controls the 
midbrain iron concentration decreased and the thalamus iron concentration increased 
while concentrations in the HFD intervention group remained unchanged from 6 to 20 
weeks. Also, alpha-synuclein expression remained elevated in the midbrain but not the 
thalamus at 20 weeks. The 20 week results confirmed our previous findings that HFD 
induced obesity resulted in increased iron concentrations in the midbrain, but the finding 
that this was due to attenuation of iron efflux rather than accumulation is novel. 
Similarly, our finding that HFD attenuated iron concentration accumulation in the 
thalamus as compared to LFD is also new to the literature on brain iron biology.   
Iron regulatory protein gene expression remained largely unchanged in the brain 
at either time point, while liver hepcidin expression showed signs of iron deficiency at 6 
weeks. Our first attempt to extract RNA using a general kit resulted in low RNA 
concentrations that were unsuitable for PCR and thus several samples from the midbrain, 
thalamus, and hippocampus were excluded from analysis. A second method using a lipid 
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tissue specific kit was successful and resulted in sufficient RNA extraction for PCR. The 
lack of significant change in Ferritin H, Ferritin L, ferroportin, transferrin receptor-1, and 
divalent metal transporter-1 expression in the brain, despite iron concentration changes 
suggested that they were either not present or our study was underpowered to detect the 
changes. Additional methods of assessment  (e.g., histology or western blot protein 
analysis) of iron-related protein distribution and concentration could help to clarify the 
mechanisms by which obesity effects iron status in the brain.  
Overall, our observations demonstrate that HFD induced obesity is sufficient to 
cause systemic iron changes as well as alter iron biology in the midbrain and thalamus of 
C57BL/6J mice at 20 weeks post weaning. Further, the results confirm the regional 
nature of brain iron biology, as the midbrain and thalamus were affected while the 
hippocampus and striatum were not. The attenuation of iron concentration changes in the 
midbrain and thalamus due to HFD is new and needs to be confirmed. Additional study 
into the mechanism(s) linking HFD induced obesity to brain iron biology also should be 
pursued. We were also able to demonstrate that HFD induced obesity causes elevation of 
alpha-synuclein gene expression and that changes in alpha-synuclein were apparent in 
regions where iron concentration was also altered.  The relevance of this finding is 
unknown, but we hypothesize that it may provide insight into the link between obesity 
and increased risk of neurodegenerative disease. Further work is needed to determine if 
these observations made during late adolescence and adulthood have relevance to disease 
progression typically associated with old age. 
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Additional research is needed to clarify the links between dietary induced obesity 
and iron metabolic profiles in the brain. Based on the information and results presented 
here the effects of developmental stage, duration of exposure, and brain region appear to 
be distinct and important. Determining if the alterations noted at 6 and 20 weeks relate to 
the duration of the diet or the developmental stage would provide valuable insight.  
Further, it would be useful to understand how changing the amount of iron or fat in the 
LFD and HFD affects iron biology systemically as well as in the brain. 
Iron is not the only divalent metal important to normal brain function and an 
evaluation of diet-induced obesity on manganese and copper biology in the brain may 
provide additional insights. A study by Erikson et al. (2004) reported that dietary iron 
deficiency resulted in accumulation of divalent metals in the globus pallidus, indicating 
that alterations in iron could be a trigger for aberrant accumulations of other metals that 
affect brain health [101]. 
Recently proposed models of Lewy body development suggest a prion-like 
disease pathology where misfolded alpha-synuclein proteins both aggregate into 
cytoplasmic lesions as well as migrate and potentiate subsequent misfolding [117]. The 
model relies on a yet undefined precipitating event to trigger the cascade of Lewy body 
formation. A review of the effects of overnutrition by Cai et al. (2012) poses a link 
between overnutrition, hypothalamic inflammation, subsequent obesity and ultimately 
potentiation of neurodegeneration [118].  Based on the results presented here, iron 
biology may prove to be a link between such disparate hypotheses.  
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In conclusion these findings support previous work indicating that obesity alters 
iron biology systemically and advances our understanding of the effect of obesity on 
brain iron biology as well as neurodegeneration. The results also support the 
epidemiological association between obesity and altered iron status using an animal 
model. Further, this work provides evidence of links between obesity, iron biology, and 
markers of neurodegeneration.  
Future study may make it possible to hone in on the mechanisms driving these 
alterations and thus fundamentally contribute to the understating of brain iron biology in 
states of health and disease. Since iron accumulation is readily identified in vivo using 
existing imaging techniques, the continuation of this work has the potential to develop 
diagnostic characteristics that may help to identify neurodegeneration prior to symptom 
onset and assess the effectiveness of treatment. Finally, this work may inform the 
discussion of the implications of overweight and obesity on long-term mental health
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